{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["13(9)"],"submitter":["Zhou Y"],"pubmed_abstract":["<h4>Background</h4>Lung cancer is a globally prevailing malignancy, and the predominant histological subtype is lung adenocarcinoma (LUAD). IL-1 receptor-associated kinase 3 (<i>IRAK3</i>) has been identified in connection with innate immune and inflammatory response. The aim of this study is to investigate the impact of <i>IRAK3</i> on prognosis and immunotherapy efficacy in LUAD, which remains incompletely elucidated.<h4>Methods</h4>Our study delved into multiple online databases to find out expression, methylation and prognostic potentials of <i>IRAK3</i> in LUAD and other malignancies. We employed tissue microarrays to assess IRAK3 protein levels in our LUAD cohort [National Cancer Center (NCC), China] and explore prognostic values. The correlations between <i>IRAK3</i> and immune infi"],"journal":["Translational lung cancer research"],"pagination":["2139-2161"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11484737"],"repository":["biostudies-literature"],"pubmed_title":["IL-1 receptor-associated kinase 3 (IRAK3) in lung adenocarcinoma predicts prognosis and immunotherapy resistance: involvement of multiple inflammation-related pathways."],"pmcid":["PMC11484737"],"pubmed_authors":["Shao F","Li Z","Zhang Z","He J","Rao W","Guo W","Zhang H","Xue Q","Tan F","Zhou Y","Liu T","Gao S"],"additional_accession":[]},"is_claimable":false,"name":"IL-1 receptor-associated kinase 3 (IRAK3) in lung adenocarcinoma predicts prognosis and immunotherapy resistance: involvement of multiple inflammation-related pathways.","description":"<h4>Background</h4>Lung cancer is a globally prevailing malignancy, and the predominant histological subtype is lung adenocarcinoma (LUAD). IL-1 receptor-associated kinase 3 (<i>IRAK3</i>) has been identified in connection with innate immune and inflammatory response. The aim of this study is to investigate the impact of <i>IRAK3</i> on prognosis and immunotherapy efficacy in LUAD, which remains incompletely elucidated.<h4>Methods</h4>Our study delved into multiple online databases to find out expression, methylation and prognostic potentials of <i>IRAK3</i> in LUAD and other malignancies. We employed tissue microarrays to assess IRAK3 protein levels in our LUAD cohort [National Cancer Center (NCC), China] and explore prognostic values. The correlations between <i>IRAK3</i> and immune infi","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Sep","modification":"2026-07-15T12:58:04.607Z","creation":"2025-04-04T22:48:04.973Z"},"accession":"S-EPMC11484737","cross_references":{"pubmed":["39430338"],"doi":["10.21037/tlcr-24-391"]}}